ArticleFrontiers in oncology2025
Identification of potential biomarkers for breast cancer based on salivary metabolomics.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salivary Metabolic Characteristics and Response to Neoadjuvant Systemic Therapy in Breast Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer (BC) remains the most prevalent malignant tumor in women worldwide and a leading cause of cancer-related mortality. Early screening is essential to improve prognosis, yet current diagnostic methods are often invasive or lack sensitivity. Saliva is an accessible and non-invasive biofluid containing various metabolites that reflect systemic physiological and pathological changes. Thus, salivary metabolomics may provide novel insights into breast cancer-associated metabolic alterations and support the development of early diagnostic strategies. Objectives: To explore the salivary metabolomic profile of breast cancer patients and identify potential non-invasive biomarkers for early breast cancer screening. Methods: Saliva samples were collected from a screening set consisting of 30 BC patients and 20 normal controls (NC) volunteers. untargeted metabolomics approach was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Principal component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA), along with KEGG pathway enrichment and receiver operating characteristic (ROC) curve analyses, were employed to characterize metabolic differences and identify potential biomarkers. Additionally, saliva samples from a validation set (52 BC patients and 52 NC volunteers) were collected. Enzyme-linked immunosorbent assay (ELISA) was used to quantify potential biomarkers, and their diagnostic performance was evaluated through ROC curve analysis. Results: A total of 101 differential metabolites were identified, including 81 upregulated and 20 downregulated compounds. Screening identified 2-aminonicotinic acid and theobromine as potential diagnostic biomarkers. Analysis of the validation set demonstrated that 2-aminonicotinic acid (AUC: 0.81, cut-off: 5.88 ng/mL) and theobromine (AUC: 0.75, cut-off: 5.27 ng/mL) exhibit promising diagnostic potential. Conclusion: The salivary metabolome of breast cancer patients displays distinct changes compared to healthy individuals. Salivary 2-aminonicotinic acid and theobromine emerge as promising non-invasive biomarkers for breast cancer detection. Nevertheless, larger-scale validation studies are warranted to substantiate their specificity and clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.